The dynamics of tumour–vasculature interaction suggests low‐dose, time‐dense anti‐angiogenic schedulings
暂无分享,去创建一个
[1] Daniel Tee,et al. Simulation of tumor-induced angiogenesis and its response to anti-angiogenic drug treatment: mode of drug delivery and clearance rate dependencies , 2003, Journal of Cancer Research and Clinical Oncology.
[2] Antonio Fasano,et al. Dynamics of tumour cords following changes in oxygen availability: A model including a delayed exit from quiescence , 2005, Math. Comput. Model..
[3] Andreas Friedl,et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Kerbel,et al. Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches , 2004, Cancer and Metastasis Reviews.
[5] Donald W Kufe,et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Folkman,et al. Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.
[7] A. d’Onofrio. A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences , 2005, 1309.3337.
[8] J. Folkman,et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.
[9] Dirk Strumberg,et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Chaplain,et al. Continuous and discrete mathematical models of tumor-induced angiogenesis , 1998, Bulletin of mathematical biology.
[11] J. Folkman. Opinion: Angiogenesis: an organizing principle for drug discovery? , 2007, Nature Reviews Drug Discovery.
[12] T. Wheldon. Mathematical models in cancer research , 1988 .
[13] Alberto Gandolfi,et al. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999). , 2004, Mathematical biosciences.
[14] P. Hahnfeldt,et al. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. , 2003, Journal of theoretical biology.
[15] R. D'Amato,et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. , 2001, Cancer research.
[16] Philip Hahnfeldt,et al. Simple ODE models of tumor growth and anti-angiogenic or radiation treatment , 2001 .
[17] F. Khuri,et al. Safety and pharmacokinetic effects of TNP-470, an angiogenesis inhibitor, combined with paclitaxel in patients with solid tumors: evidence for activity in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] C. Yiannoutsos,et al. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] G. Giaccone,et al. Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] L. Ellis,et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] G. Sledge,et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] John V Heymach,et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Y. Konishi,et al. Efficacy of the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on osteosarcoma growth and lung metastasis in rats. , 1995, Japanese journal of clinical oncology.
[24] Robert Gray,et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.
[25] F. Schramel,et al. Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] W. Gerald,et al. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers , 2006, Investigational New Drugs.
[27] P. Carmeliet,et al. Angiogenesis in cancer and other diseases , 2000, Nature.
[28] Thomas Boehm,et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.
[29] A. Stopeck,et al. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[30] Alberto Gandolfi,et al. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. , 2008, Mathematical medicine and biology : a journal of the IMA.
[31] F. Cavalli,et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[32] J. Marshall,et al. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[33] Eric Masson,et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] I. B. Borel Rinkes,et al. Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. , 2000, Cancer research.
[35] Bing Li,et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo , 1993, Nature.
[36] Peteris Daugulis,et al. Hopf point analysis for angiogenesis models , 2003 .
[37] P. Hahnfeldt,et al. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. , 1999, Cancer research.
[38] T. Shankey,et al. Cell cycle models for molecular biology and molecular oncology: exploring new dimensions. , 1999, Cytometry.
[39] Yuri Kogan,et al. Critical-point analysis for three-variable cancer angiogenesis models. , 2005, Mathematical biosciences and engineering : MBE.
[40] H M Byrne,et al. Modelling the Role of Angiogenesis and Vasculogenesis in Solid Tumour Growth , 2007, Bulletin of mathematical biology.
[41] U. Ledzewicz,et al. ANTI-ANGIOGENIC THERAPY IN CANCER TREATMENT AS AN OPTIMAL CONTROL PROBLEM , 2007 .
[42] Urszula Ledzewicz,et al. AntiAngiogenic Therapy in Cancer Treatment as an Optimal Control Problem , 2007, SIAM J. Control. Optim..
[43] E. Lin,et al. Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo , 2007 .
[44] L. Preziosi,et al. ADVECTION-DIFFUSION MODELS FOR SOLID TUMOUR EVOLUTION IN VIVO AND RELATED FREE BOUNDARY PROBLEM , 2000 .
[45] Jeffrey W. Clark,et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.
[46] S. Fox,et al. TUMOUR ANGIOGENESIS , 1996, The Journal of pathology.
[47] Urszula Foryś,et al. THREE TYPES OF SIMPLE DDE'S DESCRIBING TUMOR GROWTH , 2007 .
[48] S. McDougall,et al. Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. , 2006, Journal of theoretical biology.
[49] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[50] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[51] J. Rak,et al. Host microenvironment in breast cancer development: Inflammatory and immune cells in tumour angiogenesis and arteriogenesis , 2003, Breast Cancer Research.
[52] P. Maini,et al. A cellular automaton model for tumour growth in inhomogeneous environment. , 2003, Journal of theoretical biology.
[53] E. Perez,et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.
[54] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[55] William Arbuthnot Sir Lane,et al. Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.
[56] A. Goldhirsch,et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[57] J. Hainsworth,et al. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) , 2005 .
[58] J. Folkman,et al. Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.